Company: WHWK
Filing Date: 2025-03-31
Form Type: S-3
Source: 0001193125-25-068942
Chunk: 18

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-31
Form: S-3
Chunk 18
---
 pre-funded warrants purchased in the Private Placement by Averill Master Fund; (iii) 421,083                                                        
 shares of common stock purchased in the Private Placement by Averill Madison Master Fund, Ltd. (“Averill Madison Fund” and, together with Averill Master Fund, the “Averill Funds”); and (iv) 527,321 shares of common                                
 stock issuable upon the exercise of pre-funded warrants purchased in the Private Placement by Averill Master Fund. The pre-funded warrants may not be exercised to the                                                                                
 extent such exercise would cause the Averill Funds, together with their affiliates, to beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to such exercise. The beneficial   
 ownership amounts in the table above do not give effect to this Beneficial Ownership Limitation solely for illustrative purposes. Suvretta Capital Management, LLC is the investment manager of the Averill Funds. Aaron Cowen is a control person of 
 Suvretta Capital Management, LLC and as such may be deemed to beneficially own these shares. The principal business address of Suvretta Capital Management, LLC is 540 Madison Avenue, 7th Floor, New York, NY 10022.                                 |

| 6. | Consists of 4,166,000 shares of common stock purchased in the Private Placement by OrbiMed Genesis Master Fund,                                                                                                                                    
 L.P. (“Genesis”). OrbiMed Genesis GP LLC (“Genesis GP”) is the general partner of Genesis. OrbiMed Advisors LLC (“OrbiMed Advisors”) is the managing member of Genesis GP. OrbiMed Advisors exercises                                              
 investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis, except to the extent of its or his pecuniary 
 interest therein if any. The principal business address for each of the entities and individuals above is c/o OrbiMed Advisors LLC, 601 Lexington Avenue, 54th Floor, New York, New York.                                                          |

| 7. | Consists of (i) 1,959,162 shares of common stock purchased in the Private Placement by EcoR1 Capital Fund                                                                                                                                          
 Qualified, L.P. (“Qualified Fund”); and (ii) 122,838 shares of common stock purchased in the Private Placement by Eco